This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
CVS Health Steps Up to Bolster Oak Street as Cost Pressures Mount
by Moumi Mondal
CVS trims its outlook as Oak Street faces rising medical costs, but new leadership and tech upgrades aim for steady growth.
Zacks Industry Outlook Highlights Cigna and Humana
by Zacks Equity Research
Cigna and Humana stand out in the HMO space, leveraging growth platforms and Medicare demand despite cost and regulatory pressures.
2 HMO Stocks Poised to Thrive Despite Escalating Medical Costs
by Debasmita Chatterjee
The Medical-HMO industry benefits from strength in commercial plans, M&A and expected Medicare rate hikes, but rising costs, regulatory shifts and workforce shortages strain margins. CI and HUM are likely to navigate industry storms.
Will UnitedHealth's Push for Access to Trump Calm Investor Jitters?
by Kaibalya Pravo Dey
UNH doubles lobbying spend, reshapes legal team and seeks Trump access amid regulatory risks.
CVS Health Trades Cheaper Than Industry: How to Play the Stock?
by Moumi Mondal
CVS' diversified model, digital push and Aetna stabilization highlight a compelling investment story.
CVS Health Services' Q2 AOI Falls Despite Sales Gain: More Risk Ahead?
by Moumi Mondal
CVS Health's Q2 Health Services revenues climb 10%. Yet, AOI slips as cost pressures and Oak Street's rising MBR ail.
Food as Medicine: Elevance Health & NACHC Integrate Nutrition in Care
by Zacks Equity Research
ELV partners with NACHC to bring Food as Medicine into primary care, targeting nutritional insecurities and chronic disease.
Centene Loses 57% YTD, Incurs Loss in Q2: How to Play the Stock
by Tanuka De
CNC plunges 57% YTD after its first quarterly loss in over a decade, with analysts slashing 2025 earnings outlook by 70%.
Why Cigna (CI) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Cigna (CI) have what it takes? Let's find out.
Cigna Q2 Earnings Beat Estimates on Higher Specialty Volumes
by Zacks Equity Research
CI's Q2 earnings benefit from strong Evernorth Health Services unit, offsetting customer losses and rising costs. It continues to expect 2025 adjusted EPS at a minimum of $29.60.
Cigna (CI) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for Cigna (CI) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Cigna (CI) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Cigna (CI) delivered earnings and revenue surprises of +0.84% and +7.09%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Cigna to Report Q2 Earnings: Can Evernorth Offset Healthcare Weakness?
by Zacks Equity Research
CI's Q2 results are likely to hinge on Evernorth's growth as core healthcare revenues and premiums face steep declines.
UnitedHealth Group (UNH) Q2 Earnings Lag Estimates
by Zacks Equity Research
UnitedHealth (UNH) delivered earnings and revenue surprises of -15.70% and +0.06%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Can Optum Support UnitedHealth's Profit Amid Industry Headwinds?
by Zacks Equity Research
UNH leans on Optum's diversified growth and value-based care to counter insurance sector margin pressure in Q2.
Cigna (CI) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Cigna (CI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's Shaping CVS' Health Care Benefits Arm for the Rest of 2025?
by Moumi Mondal
CVS Health's Health Care Benefits arm posts solid Medicare gains and prepares for an ACA exit with a $448M reserve.
Why Cigna (CI) is a Top Dividend Stock for Your Portfolio
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Cigna (CI) have what it takes? Let's find out.
CVS Up on Medicare Advantage Strength: Is It a Buy Before Q2 Earnings?
by Urmimala Biswas
CVS stock surges nearly 50% in 2025, aided by strong Q1 results, raised guidance and easing Medicare regulation risks.
UnitedHealth's Commercial Unit: A Stabilizer Amid Healthcare Turmoil?
by Zacks Equity Research
UNH relies on its growing commercial insurance business as pressures from Medicare mount and industry headwinds persist.
UnitedHealth vs. Cigna: Which Insurer to Buy Amid Sector Turmoil?
by Kaibalya Pravo Dey
CI's commercial focus and clearer outlook set it apart as UNH faces guidance pulls, CEO change and rising medical costs.
Is CVS Moving Closer to Reaching Its Long-Term Low 3X Leverage Goal?
by Moumi Mondal
CVS Health inches closer to its long-term leverage target, helped by Aetna margin recovery and disciplined cash use.
Humana Expands Medicaid Footprint With Virginia's Cardinal Care Win
by Zacks Equity Research
Cardinal Care taps HUM to offer its Healthy Horizons Medicaid plan, unlocking new growth in Virginia's healthcare market.
Cigna Expands Coverage With RhinAer & Enhances Rhinitis Treatment
by Zacks Equity Research
CI to cover RhinAer for chronic rhinitis starting Sept. 15, expanding access to a minimally invasive, office-based treatment.
Zacks Industry Outlook Highlights Cigna, Humana, Centene and Molina Healthcare
by Zacks Equity Research
CNC, MOH, CI, and HUM are set to benefit from Medicare demand, steady premiums, and tech-driven growth in the HMO space.